Abstract
Viral vectors are essential for effective transgene expression in vivo. Revascularisation therapies of ischemic tissues with adenoviruses, the most commonly used vectors for gene therapy trials, encoding angiogenic growth factors remain an intriguing option for patients who cannot be treated with conventional revascularisation therapies. Adenoviruses yield very high, but transient, gene expression and are very effective in preclinical angiogenic gene therapy trials. Studies of angiogenic growth factors using adenoviral vectors in rabbit skeletal muscle have shown that even 30-fold increases in muscle perfusion can be achieved. Such increases have not been reported with any other vector or transfection technique. In clinical trials adenoviruses have been well tolerated and safe. However, only a very few positive results on clinical endpoints have been reported. In this chapter we summarise basic knowledge about adenoviruses, their strengths and weaknesses, and discuss how the strengths of adenoviruses could be better exploited to achieve positive results in future clinical trials
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Ginsberg HS. Adenoviruses. Am J Clin Pathol. 1972;57:771–776.
Yla-Herttuala S, Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med. 2003;9:694–701.
Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res. 2003;92:1098–1106.
Rissanen TT, Korpisalo P, Markkanen JE, Liimatainen T, Orden MR, Kholova I et al. Blood flow remodels growing vasculature during vascular endothelial growth factor gene therapy and determines between capillary arterialization and sprouting angiogenesis. Circulation. 2005;20;112: 3937–3946.
Puumalainen AM, Vapalahti M, Agrawal RS, Kossila M, Laukkanen J, Lehtolainen P et al. beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther. 1998;9:1769–1774.
Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A. 1997;94: 3352–3356.
Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 1993;73:309–319.
Dechecchi MC, Tamanini A, Bonizzato A, Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology. 2000;268:382–390.
Hong SS, Karayan L, Tournier J, Curiel DT, Boulanger PA. Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J. 1997;16:2294–2306.
Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT et al. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation. 2000;102:2262–2268.
Rutanen J, Turunen AM, Teittinen M, Rissanen TT, Heikura T, Koponen JK et al. Gene transfer using the mature form of VEGF-D reduces neointimal thickening through nitric oxide-dependent mechanism. Gene Ther. 2005;12:980–987.
Leppanen O, Rutanen J, Hiltunen MO, Rissanen TT, Turunen MP, Sjoblom T et al. Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits. Circulation. 2004;109:1140–1146.
Laitinen M, Mäkinen K, Manninen H, Matsi P, Kossila M, Agrawal RS et al. Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum Gene Ther. 1998;9:1481–1486.
Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med. 2004;6 Suppl 1:S164–S171.
Nalbantoglu J, Pari G, Karpati G, Holland PC. Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Hum Gene Ther. 1999;10:1009–1019.
Vajanto I, Rissanen TT, Rutanen J, Hiltunen MO, Tuomisto TT, Arve K et al. Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. J Gene Med. 2002;4:371–380.
Rutanen J, Rissanen TT, Markkanen JE, Gruchala M, Silvennoinen P, Kivela A et al. Adenoviral Catheter-Mediated Intramyocardial Gene Transfer Using the Mature Form of Vascular Endothelial Growth Factor -D Induces Transmural Angiogenesis in Porcine Heart. Circulation. 2004;109: 1029–1035.
Poliakova L, Kovesdi I, Wang X, Capogrossi MC, Talan M. Vascular permeability effect of adenovirus-mediated vascular endothelial growth factor gene transfer to the rabbit and rat skeletal muscle. J Thorac Cardiovasc Surg. 1999;118:339–347.
Thirion C, Lochmuller H, Ruzsics Z, Boelhauve M, Konig C, Thedieck C et al. Adenovirus vectors based on human adenovirus type 19a have high potential for human muscle-directed gene therapy. Hum Gene Ther. 2006;17:193–205.
Sinnreich M, Shaw CA, Pari G, Nalbantoglu J, Holland PC, Karpati G. Localization of coxsackie virus and adenovirus receptor (CAR) in normal and regenerating human muscle. Neuromuscul Disord. 2005;15:541–548.
Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, Kivela A et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation. 2003;107: 2677–2683.
Makinen K, Manninen H, Hedman M, Matsi P, Mussalo H, Alhava E et al. Increased Vascularity Detected by Digital Subtraction Angiography after VEGF Gene Transfer to Human Lower Limb Artery: A Randomized, Placebo-Controlled, Double-Blinded Phase II Study. Mol Ther. 2002;6:127–133.
Wirth T, Hedman M, Mäkinen K, Manninen H, Immonen A, Vapalahti M et al. Safety Profile of Plasmid/Liposomes and Virus Vectors in Clinical Gene Therapy. Current Drug Safety. 2006;1: 253–257.
Chen P, Kovesdi I, Bruder JT. Effective repeat administration with adenovirus vectors to the muscle. Gene Ther. 2000;7:587–595.
Alba R, Bosch A, Chillon M. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther. 2005;12Suppl 1:S18–27.:S18–S27.
Dor Y, Djonov V, Abramovitch R, Itin A, Fishman GI, Carmeliet P et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 2002;21:1939–1947.
Arsic N, Zentilin L, Zacchigna S, Santoro D, Stanta G, Salvi A et al. Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. Mol Ther. 2003;7:450–459.
Ylä-Herttuala, S., Rissanen, T., Vajanto, I., Hartikainen, J. Vascular endothelial growth factors – biology and current status of clinical applications in cardiovascular medicine. Journal of the American Cardiology of College. 2007. Ref Type: In Press
Zaiss AK, Muruve DA. Immune responses to adeno-associated virus vectors. Curr Gene Ther. 2005;5:323–331.
Mangeat B, Trono D. Lentiviral vectors and antiretroviral intrinsic immunity. Hum Gene Ther. 2005;16:913–920.
Mäkinen, K., Laitinen, M., Manninen, H., Matsi, P., Alhava, E., Ylä-Herttuala, S. Catheter-mediated VEGF gene transfer to human lower limb arteries after PTA. Circulation 100(18), I-770. 2-11-1999.
Rajagopalan S, Shah M, Luciano A, Crystal R, Nabel EG. Adenovirus-mediated gene transfer of vegf(121) improves lower-extremity endothelial function and flow reserve. Circulation. 2001;104:753–755.
Rajagopalan S, Trachtenberg J, Mohler E, Olin J, McBride S, Pak R et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. Am J Cardiol. 2002;90:512–516.
Crystal RG, Harvey BG, Wisnivesky JP, O’Donoghue KA, Chu KW, Maroni J et al. Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum Gene Ther. 2002;13:65–100.
Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther. 2006.
Rajagopalan S, Mohler ER, III, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003;108:1933–1938.
Rissanen TT, Markkanen JE, Arve K, Rutanen J, Kettunen MI, Vajanto I et al. Fibroblast growth factor-4 induces vascular permeability, angiogenesis, and arteriogenesis in a rabbit hind limb ischemia model. FASEB J. 2003;17:100–102.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer
About this chapter
Cite this chapter
Korpisalo, P., Rissanen, T.T., Ylä-Herttuala, S. (2007). The Strengths and Weaknesses of VEGF Adenovirus-Driven Angiogenesis. In: Deindl, E., Kupatt, C. (eds) Therapeutic Neovascularization–Quo Vadis?. Springer, Dordrecht. https://doi.org/10.1007/1-4020-5955-8_2
Download citation
DOI: https://doi.org/10.1007/1-4020-5955-8_2
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-5954-4
Online ISBN: 978-1-4020-5955-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)